PFM Health Sciences’s Sarepta Therapeutics SRPT Stock Holding History

PFM Health Sciences’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-50,809	Closed	-$3.24M	–	71
2025 Q1	$3.24M	Sell	50,809 -49,363	-49%	-$5.2M	0.24%	47
2024 Q4	$12.2M	Buy	100,172 +11,956	+14%	+$1.47M	0.75%	36
2024 Q3	$11M	Hold	88,216	–	–	0.62%	37
2024 Q2	$13.9M	Buy	88,216 +76,925	+681%	+$9.88M	0.69%	41
2024 Q1	$1.46M	Buy	+11,291	New	+$1.38M	0.07%	85
2023 Q4	–	Sell	-250,967	Closed	-$30.4M	–	75
2023 Q3	$30.4M	Buy	250,967 +85,202	+51%	+$9.63M	1.43%	31
2023 Q2	$19M	Buy	+165,765	New	+$21.4M	0.74%	45
2019 Q3	–	Sell	-546,786	Closed	-$83.1M	–	100
2019 Q2	$83.1M	Buy	+546,786	New	+$66.5M	1.58%	21
2018 Q4	–	Sell	-122,490	Closed	-$19.8M	–	121
2018 Q3	$19.8M	Buy	+122,490	New	+$16.7M	0.29%	91

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

PFM Health Sciences's SRPT Position: Q2 2025 in Review

PFM Health Sciences sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 50,809 shares — an estimated $3.24M sold.

PFM Health Sciences first reported a position in SRPT in Q3 2018 and held it in 9 quarters. The position peaked at $83.1M in Q2 2019. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

PFM Health Sciences reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
PFM Health Sciences sold 50,809 Sarepta Therapeutics shares in Q2 2025, an estimated $3.24M.
PFM Health Sciences first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 9 quarters.
PFM Health Sciences's Sarepta Therapeutics position peaked at $83.1M in Q2 2019.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on PFM Health Sciences's 13F filing for Q2 2025, filed 14 Aug 2025.